LMR Partners LLP Has $4.94 Million Stake in Glaukos Co. (NYSE:GKOS)

LMR Partners LLP cut its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 11.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 32,929 shares of the medical instruments supplier's stock after selling 4,057 shares during the period. LMR Partners LLP owned 0.06% of Glaukos worth $4,937,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in GKOS. Barclays PLC grew its position in Glaukos by 394.4% in the 3rd quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier's stock worth $11,686,000 after purchasing an additional 71,556 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Glaukos by 80.1% in the third quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier's stock valued at $2,031,000 after buying an additional 6,948 shares during the period. Oak Ridge Investments LLC acquired a new stake in Glaukos during the fourth quarter worth about $1,672,000. LVW Advisors LLC grew its position in Glaukos by 22.2% during the fourth quarter. LVW Advisors LLC now owns 2,273 shares of the medical instruments supplier's stock worth $341,000 after buying an additional 413 shares in the last quarter. Finally, Zhang Financial LLC bought a new position in Glaukos during the fourth quarter valued at about $221,000. Institutional investors and hedge funds own 99.04% of the company's stock.

Glaukos Stock Up 4.2%

Shares of NYSE GKOS traded up $3.83 during trading hours on Friday, hitting $95.45. The company had a trading volume of 773,079 shares, compared to its average volume of 685,745. Glaukos Co. has a 1-year low of $77.10 and a 1-year high of $163.71. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm's 50 day moving average is $93.95 and its 200-day moving average is $126.28. The stock has a market capitalization of $5.45 billion, a P/E ratio of -33.26 and a beta of 0.83.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. During the same period last year, the business posted ($0.70) earnings per share. The business's revenue for the quarter was up 24.6% compared to the same quarter last year. On average, analysts expect that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on GKOS. Piper Sandler lowered their price objective on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 15th. Needham & Company LLC lowered their price target on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Morgan Stanley reduced their price objective on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Truist Financial reiterated a "buy" rating and set a $135.00 target price (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Finally, Stifel Nicolaus dropped their price objective on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Glaukos has a consensus rating of "Moderate Buy" and a consensus price target of $134.67.

Insider Buying and Selling

In related news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. The trade was a 2.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.80% of the stock is owned by company insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.